

REVIEW

Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS

N Murataeva, A Straiker and K Mackie

*Department of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA***Correspondence**

K Mackie, Department of Psychological and Brain Sciences, Indiana University, 1101 E. 10th Street, Bloomington, IN 47405, USA.

E-mail: kmackie@indiana.edu

Keywords

2-AG; synaptic plasticity; metabolism; synthesis; diacylglycerol; arachidonic acid; hydrolysis; cannabinoid; monoacylglycerol lipase

Received

13 June 2013

Revised

29 August 2013

Accepted

8 September 2013

The endogenous cannabinoid signalling system, composed of endogenous cannabinoids, cannabinoid receptors and the enzymes that synthesize and degrade the endogenous cannabinoids, is much more complex than initially conceptualized. 2-Arachidonoylglycerol (2-AG) is the most abundant endocannabinoid and plays a major role in CNS development and synaptic plasticity. Over the past decade, many key players in 2-AG synthesis and degradation have been identified and characterized. Most 2-AG is synthesized from membrane phospholipids via sequential activation of a phospholipase C β and a diacylglycerol lipase, although other pathways may contribute in specialized settings. 2-AG breakdown is more complicated with at least eight different enzymes participating. These enzymes can either degrade 2-AG into its components, arachidonic acid and glycerol, or transform 2-AG into highly bioactive signal molecules. The implications of the precise temporal and spatial control of the expression and function of these pleiotropic metabolizing enzymes have only recently come to be appreciated. In this review, we will focus on the primary organization of the synthetic and degradative pathways of 2-AG and then discuss more recent findings and their implications, with an eye towards the biological and therapeutic implications of manipulating 2-AG synthesis and metabolism.

LINKED ARTICLES

This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit <http://dx.doi.org/10.1111/bph.2014.171.issue-6>

Abbreviations

2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; ABHD6, serine hydrolase α - β -hydrolase domain 6; ABHD12, serine hydrolase α - β -hydrolase domain 12; AEA, anandamide; CaMKII, calcium calmodulin kinase II; DAGL, diacylglycerol lipase; DSE, depolarization-induced suppression of excitation; DSI, depolarization-induced suppression of inhibition; FAAH, fatty acid amide hydrolase; LPA, lysophosphatidic acid; LTD, long-term depression; lyso-PLC, lyso phospholipase C; MAG, monoacylglycerol; MAGL, monoacylglycerol lipase; mGluR, metabotropic glutamate receptor; MSE, metabotropic suppression of excitation; PIP₂, phosphatidylinositol 4,5-bisphosphate; THC, Δ^9 -tetrahydrocannabinol

Introduction

Humans have used *Cannabis sativa* for at least 8000 years for recreational and therapeutic purposes (Zuardi *et al.*, 2006). Its chief psychoactive component is Δ^9 -tetrahydrocannabinol (THC), which was chemically characterized in 1965 (Mechoulam and Gaoni, 1965). THC engages several receptors, including the cannabinoid CB₁ and CB₂ receptors (receptor nomenclature follows Alexander *et al.*, 2013). These receptors are a part of the endogenous cannabinoid (endocannabinoid) signalling system, which regulates analgesia,

memory, synaptic plasticity, learning, appetite, peripheral metabolism, immune function and many other physiological processes (Hohmann *et al.*, 1995; Di Marzo *et al.*, 1998; Cravatt *et al.*, 2001; Brenowitz and Regehr, 2005; Kishimoto and Kano, 2006). Thus, understanding endocannabinoid signalling is pivotal to understanding the complex networks regulating these diverse processes.

The gene for the first cannabinoid receptor, CB₁, was cloned in 1990 (Matsuda *et al.*, 1990). This receptor is found throughout the nervous system (Herkenham *et al.*, 1990) and is also present in certain cells of the immune system, adipose

tissue, liver, muscle, reproductive cells, kidney and lungs (Pagotto *et al.*, 2006). CB₁ receptors belong to the GPCR family (Mukhopadhyay and Howlett, 2001), are involved in regulating many neuronal networks (Kano *et al.*, 2009) and are the most highly expressed GPCRs in the brain (Devane *et al.*, 1988; Herkenham *et al.*, 1990).

The gene for the second cannabinoid receptor, CB₂, was cloned in 1993. These receptors have 44% amino acid homology to the CB₁ receptor (Munro *et al.*, 1993) and are most abundant in immune cells and their descendants (Galiegue *et al.*, 1995). However, the extent of CB₂ receptor expression is unclear and the precise distribution of CB₂ receptors, especially in the nervous system, is still debated (Atwood *et al.*, 2012).

The endocannabinoids are the signalling components of the endocannabinoid system. Although peptides that interact with CB₁ receptors (the peptans; Bauer *et al.*, 2012), including the peptide hemopressin (Heimann *et al.*, 2007), have been described, the focus of this review will be on the synthesis and degradation of lipid endocannabinoids, particularly 2-arachidonoylglycerol (2-AG). The endocannabinoids bind to CB receptors, but vary in their affinity, efficacy and metabolism. The two most studied endocannabinoids are N-arachidonoyl ethanolamine, also known as anandamide (AEA), and 2-AG. Lipid endocannabinoids are membrane-preferring; they can diffuse across membranes but do not participate in vesicle-mediated release. As a consequence, endocannabinoids are thought to be synthesized enzymically 'on demand' from lipid precursors (Di Marzo *et al.*, 1998). However, some evidence suggests that in certain cases, 2-AG might be preformed and sequestered until needed (Alger and Kim, 2011). This possibility is based on the observation that inhibitors of the main synthetic enzyme for 2-AG are sometimes unable to block 2-AG-dependent responses (Chevalyre and Castillo, 2003). However, a recent paper challenges the notion of preformed 2-AG pools, making the argument that experimental conditions may explain the discrepancies (Hashimoto *et al.*, 2013).

2-AG has been implicated in a wide variety of physiological processes, including several forms of neuroplasticity (Kano *et al.*, 2009). In addition to its signalling roles, 2-AG is also an important intermediate in lipid metabolism (Ahn *et al.*, 2008). Thus, measurement of 2-AG from tissue samples represents both 'signalling' and 'metabolic-intermediate' levels of 2-AG and it is likely that only a small fraction of the 2-AG measured in tissue samples is functioning as an endocannabinoid (Caille *et al.*, 2007). The synthesis of 2-AG appears to occur through relatively few pathways, but its degradation is more complex. The best studied synthetic pathways for 2-AG are its synthesis from diacylglycerols (DAG) with arachidonic acid at the 2-position (Stella *et al.*, 1997) by one of two diacylglycerol lipases (DAGL) – DAGL α and DAGL β (Bisogno *et al.*, 2003). In addition, 2-AG can also be synthesized by dephosphorylation of arachidonoyl-LPA (Nakane *et al.*, 2002) or by the sequential action of PLA1 and a lyso phospholipase C (lyso-PLC) (Higgs and Glomset, 1994).

The metabolism of 2-AG is more complicated in that several enzymes, operating in different compartments and contexts, are involved. Enzymes metabolising 2-AG are located both post-synaptically and pre-synaptically (Blankman *et al.*, 2007; Kano *et al.*, 2009; Straiker *et al.*, 2011).

This provides several parallel mechanisms for spatial control of endocannabinoid signalling. Additional spatial specificity may be imparted by the subcellular localization of the enzymes as GPCR signalling is often restricted to certain organelles (Caille *et al.*, 2007). Monoacylglycerol lipase (MAGL) is considered to be the chief 2-AG degrading enzyme, but at least three other serine hydrolases also contribute: fatty acid amide hydrolase (FAAH), serine hydrolase α - β -hydrolase domain 6 (ABHD6) and serine hydrolase α - β -hydrolase domain 12 (ABHD12) (Blankman *et al.*, 2007). All of these pathways lead to two major 2-AG breakdown products: arachidonic acid (AA) and glycerol (Freund *et al.*, 2003). Additional routes of 2-AG metabolism produce new signalling molecules. For example, COX-2 oxidizes 2-AG under certain circumstances (Straiker *et al.*, 2011), producing prostaglandin glycerol esters (Sang *et al.*, 2007; Hu *et al.*, 2008; Richie-Jannetta *et al.*, 2010). Phosphorylation of 2-AG by acyl glycerol kinase(s) creates lysophosphatidic acid (LPA) (Bektas *et al.*, 2005), which activates different signalling pathways (Moolenaar *et al.*, 1997). Finally, lipoxygenases can oxidize 2-AG, producing hydroperoxy derivatives of 2-AG (Kozak and Marnett, 2002). The bioactive role of these latter 2-AG metabolites is often opposite to that of 2-AG (e.g. excitatory rather than inhibitory). Therefore, inhibiting the metabolic enzymes can have profound cellular consequences. The complexity of 2-AG regulatory mechanisms (Figure 1) is considerable and deserves a closer examination. This review summarizes recent major discoveries in the areas of 2-AG synthesis and metabolism in the CNS.

Three major pathways for 2-AG synthesis

Three major pathways have been proposed for 2-AG synthesis (Figure 2). The first is the production of 2-AG via a two-step process, starting with phosphatidylinositol 4,5-bisphosphate (PIP₂) proceeding via a DAG intermediate to 2-AG (Farooqui *et al.*, 1989). The first step is catalysed by a phospholipase C- β (PLC β) (Farooqui *et al.*, 1989), whereas the second step is catalysed by one of two DAGLs (Bisogno *et al.*, 2003; Tanimura *et al.*, 2010). This pathway appears to dominate in the CNS (Kano *et al.*, 2009). The second pathway involves the conversion of phosphatidyl lipid (e.g. PI) to 2-arachidonoyl-lyso PI, by the action of a PLA1, and then to 2-AG by the action of lyso-PLC (Higgs and Glomset, 1994) (Figure 2). The third pathway involves LPA hydrolysis by an LPA phosphatase (Nakane *et al.*, 2002). The involvement of these latter two pathways in the production of 2-AG in the CNS has not been evaluated in detail but may account for some reports of endocannabinoid-mediated synaptic plasticity that is insensitive to DAGL inhibitors (Zhang *et al.*, 2011).

Two DAGL isoforms produce 2-AG

Two DAGL isoforms have been identified – DAGL α and DAGL β (Bisogno *et al.*, 2003). DAGLs are highly conserved between species, with human and mouse DAGL α sharing 97% homology and the DAGL β s sharing 79% homology. The




Figure 1

2-AG trafficking and its action at the synapse. (A) 2-AG synthesis and breakdown. Schematic representation of an excitatory terminal and post-synaptic spine. Conventional action potential-induced neurotransmitter release (e.g. glutamate) occurs via activation of calcium channels adjacent to transmitter-filled vesicles, which fuse with the membrane to release their contents. 2-AG can be produced either following synaptic depolarization (e.g. DSE) or by activation of $G_{q/11}$ -coupled GPCRs, such as group I mGlu receptors, which then activate PLC β (PLC β , cleaving phosphatidyl bisphosphate (PIP $_2$) into DAG and inositol trisphosphate (IP $_3$)). DAG is hydrolysed by DAG lipase, yielding 2-AG. Rather than being released from vesicles, lipophilic endocannabinoids cross the membrane, perhaps utilizing facilitated transport. The mechanism of subsequent passage across the synapse is unknown but may involve carrier proteins. Activation of pre-synaptic CB_1 receptors inhibits transmitter release by inhibiting Ca^{2+} channels. On the post-synaptic side, 2-AG can be broken down into glycerol and AA by the enzyme ABHD6, embedded in the membrane. On the pre-synaptic side, 2-AG can be broken down by MAGL, loosely associated with the plasma membrane, or, in principle, by ABHD12, a transmembrane protein, into glycerol and AA. (B) ABHD12 localization on Golgi. Emerging evidence suggests that ABHD12 is embedded in the Golgi membrane, with its active site facing the lumen.




Figure 2

Primary routes of 2-AG synthesis and degradation. 2-AG synthesis can potentially occur from three precursors: (1) DAG (via DAGL), in turn, DAG can be synthesized from PIP₂ via PLCβ; (2) 2-Arachidonoyl-LPI via 2-LPA phosphatase; and (3) 2-Arachidonoyl-LPI via a lyso-PLC. 2-Arachidonoyl-LPI can, in turn, be synthesized from PI via the actions of PLA1 (PIP₂ phosphatases produce PI from PIP₂). 2-AG metabolism can potentially occur via five different routes: (1) MAGL, FAAH, ABHD6 and ABHD12 hydrolyse 2-AG into AA and glycerol; (2) COX-2 converts 2-AG into PGE₂-G; (3) MAG kinase converts 2-AG into 2-arachidonoyl-LPA (2-LPA phosphatase reverses the actions of MAG kinase); (4) cytochrome p450 converts 2-AG into 11,12-EET and (5) 12-lipoxygenase (12-LOX) can oxygenate 2-AG into 12-HETE-G.

two enzymes differ from each other by the presence of a long C-terminal tail (~300 amino acids) in DAGL α relative to DAGL β (Oudin *et al.*, 2011). The C-terminal tail in DAGL α facilitates its regulation by calcium calmodulin kinase II (CaMKII), which phosphorylates serine residues in this region, decreasing DAGL α activity (Shonesy *et al.*, 2013). In mice expressing an activation-impaired form of CaMKII (T268A), both DAGL activity and 2-AG production are increased (Shonesy *et al.*, 2013). Homer, an important post-synaptic scaffolding protein (Szumliński *et al.*, 2006), appears to be involved in targeting of DAGL α towards group I metabotropic glutamate receptors (mGluRs) in dendritic spines (Jung *et al.*, 2007; Oudin *et al.*, 2011). Moreover, in murine DAGL α , the amino acid residues 973–980 comprise a consensus motif, PPxxF, for binding the coiled-coil domain of homer proteins (Jung *et al.*, 2007). Interestingly, homer 1a, which lacks the ability to partner with other homers and disrupts synaptic scaffolding, decreases group I mGluR-mediated synaptic plasticity, while enhancing depolarization-induced suppression of excitation (DSE) (Roloff *et al.*, 2010), emphasizing the importance of DAGL's spatial localization in fine-tuning synaptic plasticity.

Localization of DAGL α and DAGL β appears to be complementary and tissue-specific

DAGL α mRNA is expressed throughout the brain, but most notably in the hippocampus, striatum, ventral tegmental area and cerebellum; DAGL β 's expression pattern is not as well characterized (Oudin *et al.*, 2011). The highest levels of DAGL α mRNA are found in hippocampal pyramidal cells, dentate granule cells and cerebellar Purkinje cells. In contrast, the highest levels of DAGL β mRNA are present in the cerebellar granular layer; with low levels in the hippocampal pyramidal cell layer and thalamus (Yoshida *et al.*, 2006). In adult brain, DAGL α is generally found post-synaptically where it is enriched in the plasma membrane of dendritic spines, particularly in the spine neck (Katona *et al.*, 2006; Yoshida *et al.*, 2006; Jung *et al.*, 2007; Ludanyi *et al.*, 2011). Much less is known about the subcellular distribution of DAGL β , although recent evidence suggests that it is more broadly expressed in dendrites of cultured hippocampal neurons than is DAGL α (Jain *et al.*, 2013). At excitatory synapses, CB $_1$ receptors and DAGL α are found in close proximity – CB $_1$ receptors are pre-synaptic and DAGL α is post-synaptic (Katona *et al.*, 2006; Yoshida *et al.*, 2006). This consistent spatial arrangement of 2-AG synthesis and effector sites at excitatory synapses appears to facilitate precise control of 2-AG release towards CB $_1$ receptors. Importantly, whereas CB $_1$ receptors and DAGL α are closely apposed at excitatory synapses, CB $_1$ receptors at inhibitory synapses can be quite distant from detectable DAGL α (Katona *et al.*, 2006; Yoshida *et al.*, 2006).

The distribution of DAGL α and DAGL β changes markedly during development. In developing mouse forebrain projection neurons, DAGLs are often co-expressed with CB $_1$ receptors in elongating axons (Bisogno *et al.*, 2003; Mulder *et al.*, 2008; Keimpema *et al.*, 2010; Wu *et al.*, 2010). However, post-natally CB $_1$ receptors concentrate in axon terminals, whereas

the DAGLs accumulate in dendrites (Keimpema *et al.*, 2011). In summary, both DAGL α and DAGL β are widely distributed. Prenatally, both tend to be expressed in axons, whereas post-natally they are found in dendrites and dendritic spines.

DAGL α and DAGL β function

Studies using pharmacological inhibition of DAGLs implicate these enzymes in 2-AG-mediated synaptic plasticity (Kano *et al.*, 2002; 2009). However, these inhibitors do not distinguish between DAGL α and DAGL β , making it impossible to determine which of the two DAGLs is involved in 2-AG production. The development of three independent lines each of DAGL α and DAGL β knockout (KO) mice has helped in this regard (Gao *et al.*, 2010; Tanimura *et al.*, 2010; Yoshida *et al.*, 2011). All reported essentially the same finding: the absence of DAGL α eliminates every form of synaptic plasticity examined. These results appeared to fully resolve the question of which DAGL mediates synaptic plasticity in favour of DAGL α , although it leaves unresolved the role of the relatively abundant DAGL β in neurons.

If a DAGL plays a major role in 2-AG synthesis, 2-AG levels would be predicted to decline in the corresponding DAGL KO mice. Indeed, Tanimura *et al.* (2010) found significant decreases in 2-AG levels in both DAGL α -/- and DAGL β -/- mice. However, there were major differences among tissues. For example, in the CNS of DAGL α -/- mice, there is an 80% decrease in 2-AG levels and a 50% decrease in 2-AG levels in the CNS of DAGL β -/- mice. However, in the liver of DAGL β -/- mice, there is an ~90% reduction in 2-AG levels and in the DAGL α -/- mice 2-AG is only reduced by 50% (Gao *et al.*, 2010). This underscores the notion that either enzyme may be important for 2-AG production in a tissue-dependent fashion. For example, an ethanol-rich diet up-regulates hepatic DAGL β expression, leading to steatosis (Jeong *et al.*, 2008) and DAGL β mediates certain pro-inflammatory responses in peritoneal macrophages (Hsu *et al.*, 2012). Cerebral morphology was unaffected in either DAGL α or DAGL β KO mice (Tanimura *et al.*, 2010). Functionally, however, adult neurogenesis in the dentate gyrus and sub-ventricular zone was diminished in both DAGL α -/- and DAGL α +/- mice, but lack of DAGL β had no measurable effect (Gao *et al.*, 2010). Loss of one DAGL did not affect mRNA for the other DAGL nor did it alter the levels of MAGL, FAAH, CB $_1$ or CB $_2$ receptor mRNA (Gao *et al.*, 2010).

Whereas these experiments strongly argue for an exclusive role for DAGL α in endocannabinoid-mediated synaptic plasticity, KO studies using constitutive deletions have limitations insofar as developmental adaptations to the absence of a protein may have long-term or secondary effects that are difficult to predict. For example, in the brain, spinal cord and liver of DAGL α -/- mice, AEA levels are decreased despite this enzyme not having a direct role in AEA synthesis (Gao *et al.*, 2010).

A recent study using RNAi knockdown in cultured hippocampal neurons suggests that DAGL α and DAGL β can cooperate to mediate two forms of endocannabinoid plasticity: DSE and metabotropic suppression of excitation (MSE) (Jain *et al.*, 2013). In these experiments, DSE was diminished by knockdown of either DAGL and reduced

almost completely when both enzymes were knocked down, consistent with a cooperative effect. Similarly, knockdown of either DAGL decreased MSE mediated by mGluR5. This indicates that at the very least, DAGL β is capable of eliciting endocannabinoid-mediated synaptic plasticity under some conditions and that the two enzymes can share this function in the same neuron. Hopefully, it will also motivate studies using inducible DAGL α and DAGL β KO mice to assess more thoroughly the role of these two enzymes in 2-AG production.

In summary, 2-AG production appears to occur chiefly via the two DAGLs, but which isoform is actually responsible still remains to be established. 2-AG function, the location of its metabolic enzymes and CB $_1$ receptors all undergo a pronounced developmental change from a predominantly pre-synaptic path-finding role in the developing CNS to a primarily post-synaptic neuromodulatory role in the mature CNS. DAGL α activity is highly regulated, including stimulation by increases in intracellular calcium (Bisogno *et al.*, 2003) and increase in substrate (DAG) by activation of PLC β , and inhibition by CaMKII phosphorylation and disrupted targeting by homer 1a (Jung *et al.*, 2007; Kano *et al.*, 2009; Won *et al.*, 2009; Roloff *et al.*, 2010). Attempts to harness the cannabinoid system for therapeutic purposes have focused on synthetic receptor agonists and antagonists and, to a lesser extent, inhibitors of enzymic breakdown. However, the enzymes that produce and regulate the production of 2-AG may offer alternative targets for particular indications.

When the job is (partially) done: 2-AG metabolism

Much evidence supports the notion that in the mature CNS, 2-AG frequently acts as a retrograde synaptic signal, produced pre-synaptically and acting post-synaptically. As 2-AG traverses the synaptic cleft and reaches the pre-synaptic terminal, it enters into the membrane, where it can bind to the CB $_1$ receptor. In the pre-synapse, 2-AG can diffuse beyond the CB $_1$ receptor, possibly engaging other targets. Therefore, its prompt metabolism is important to avoid unintended actions. In addition, 2-AG also serves as an important intermediate in lipid metabolism (Ho and Randall, 2007). Our understanding of 2-AG metabolism has increased in recent years in large part due to the development of specific inhibitors and several lines of KO mice. This section will summarize many of those findings and identify key questions that remain regarding the details of 2-AG metabolism.

2-AG can be broken down or modified by a diverse assortment of enzymes that either hydrolyse it into its component parts (AA and glycerol) or chemically transform it by acylating or phosphorylating the glycerol or oxidizing its AA moiety (Figure 2). Enzymes involved in hydrolysis include MAGL, ABHD6, ABHD12 and FAAH (Blankman *et al.*, 2007). Enzymes involved in chemical transformation include COX-2 (Kozak *et al.*, 2000), cytochrome P450 (Chen *et al.*, 2008), lipoxygenases (Maccarrone *et al.*, 2000), monoacylglycerol (MAG) kinases (Kano *et al.*, 1986) and MAG acyl transferases (Coleman and Haynes, 1986).

When considering studies investigating the enzymes involved in 2-AG degradation, it is important to distinguish

between results from *in vitro* experiments, which address the question of whether a particular enzyme *can* metabolize 2-AG, and those from *in vivo* experiments that address the question of whether the enzyme has *physiological relevance* in a particular context. It is well accepted that MAGL is the dominant enzyme in degrading 2-AG in its endocannabinoid retrograde messenger role, but at least four other enzymes – ABHD6, ABHD12, FAAH and COX-2 – have important, but more specialized roles in endocannabinoid retrograde signalling. Studies examining 2-AG metabolism raise intriguing questions that we will address below: Which of these enzymes are active members of an endogenous 2-AG-based cannabinoid signalling system? Where are they found and when do they contribute? Do they act cooperatively or in a division of roles? For example, does one enzyme engage in bulk clearance of 2-AG at the pre-synaptic terminal while another breaks down the neurotransmitter on the post-synaptic side? Does their activity level or function depend on the cell type that they are expressed in?

MAGL is responsible for acute breakdown of 2-AG, and more . . .

MAGL is primarily pre-synaptically localized (Gulyas *et al.*, 2004). It contains 302 amino acids, with its catalytic triad, Ser¹²², Asp²³⁹ and His²⁶⁹ located in turns between α -helices and β -sheets (Karlsson *et al.*, 1997). In addition, MAGL contains an HG-dipeptide (His⁴⁹ and Gly⁵⁰) motif common to all lipases (Karlsson *et al.*, 2001). Moreover, three cysteine residues, Cys²⁴² (King *et al.*, 2009), Cys²⁰¹ and Cys²⁰⁸ (Jaeger *et al.*, 1999), regulate MAGL function, as their mutation decreases hydrolytic activity. In addition, molecular and Western blotting evidence supports the existence of several MAGL splice variants (Karlsson *et al.*, 2001). MAGL is localized intracellularly and is found in both soluble and membrane fractions (Blankman *et al.*, 2007). It is pre-synaptic and a loosely membrane-associated location is ideal to break down 2-AG in the proximity of CB $_1$ receptors. Our understanding of the prominent role of MAGL in degrading 2-AG in the CNS comes from the observation that inhibiting or knocking out MAGL leads to large increases in brain 2-AG levels. For example, in MAGL $-/-$ mice, 2-AG levels increase 58-fold (Taschler *et al.*, 2011). The quantitatively dominant role of MAGL among other serine hydrolases in hydrolysing 2-AG comes from an experiment where 32 serine hydrolases expressed in the brain were tested for their ability to hydrolyse 2-AG. The great majority of 2-AG was hydrolysed by MAGL (Blankman *et al.*, 2007). Evidence for a role of MAGL in terminating the action of retrogradely released 2-AG comes from experiments where endocannabinoid (2-AG)-mediated synaptic plasticity is prolonged in slices or cultured neurons prepared from MAGL KO animals (Kano *et al.*, 2009; Straiker and Mackie, 2009).

Complete pharmacological or genetic inactivation of MAGL increases endocannabinoid tone and causes CB $_1$ receptor desensitization, tolerance to CB $_1$ receptor agonists and down-regulation of CB $_1$ receptors (Chanda *et al.*, 2010; Schlosburg *et al.*, 2010). These findings emphasize the importance of MAGL as an enzyme playing a major role in

hydrolysing synaptic 2-AG. An important practical question is how much MAGL inhibition is necessary for CB₁ receptor desensitization and is there a therapeutic window where pharmacologically useful MAGL inhibition occurs, without desensitization of CB₁ receptor signalling?

2-AG hydrolytic activity in brain membranes from MAGL mice lacking just one allele (MAGL^{+/-}) was about half of that of wild-type mice (Schlosburg *et al.*, 2010). 2-AG levels in these animals were also significantly elevated (about twice over wild-type levels) (Schlosburg *et al.*, 2010). The twofold increase in 2-AG levels did not significantly desensitize CB₁ receptors (Schlosburg *et al.*, 2010). This suggests that MAGL activity can be significantly reduced and 2-AG levels mildly elevated, before CB₁ receptor desensitization occurs. A number of investigators have studied the effects of chronic MAGL inhibition by JZL184 in mice (Busquets-Garcia *et al.*, 2011; Kinsey *et al.*, 2011; Sumislawski *et al.*, 2011; Ghosh *et al.*, 2013). These studies suggest that chronic (typically ~1 week) parenteral dosing of up to and including 8 mg·kg⁻¹·day⁻¹ of JZL184 does not lead to behavioural tolerance or CB₁ receptor desensitization (Busquets-Garcia *et al.*, 2011; Kinsey *et al.*, 2011; Ghosh *et al.*, 2013). However, a chronic JZL184 dose of 16 mg·kg⁻¹·day⁻¹ reliably produces tolerance (Sumislawski *et al.*, 2011; Ghosh *et al.*, 2013). Whereas there may be variation between tissues and behaviours, there appears to be a therapeutic window (between 8 and 16 mg·kg⁻¹ of JZL184) of MAGL inhibition, where behavioural efficacy is intact and CB₁ receptor signalling is maintained.

Interestingly, in both MAGL KO mice and animals treated with a MAGL inhibitor, in addition to the expected increase in 2-AG brain levels, there was a profound decrease in levels of free AA (Long *et al.*, 2009). It is likely that inhibition of 2-AG degradation via MAGL attenuates AA-based lipid production. Consistent with this idea, several eicosanoids, including PGE₂, PGD₂, PGF_{2α} and thromboxane B₂, were decreased (Nomura *et al.*, 2011). Interestingly, MAGL inhibitors prevented the rise in brain eicosanoids and inflammatory cytokines seen following LPS injection, without affecting basal cytokine levels. Moreover, the reduction in activated cytokines was not reversed by CB₁ receptor antagonists, but was mimicked by COX-1 blockade (Nomura *et al.*, 2011), suggesting they were due to COX-1 metabolites and not CB₁ receptor activation. These findings suggest that MAGL inhibition may be an effective therapeutic option for neuroinflammatory conditions. Thus, MAGL is an important enzyme both in regulating synaptic 2-AG-based signalling as well as in controlling brain eicosanoid production.

ABHD6: a post-synaptic guard against 2-AG overproduction?

ABHD6 first drew attention as a 2-AG metabolizing enzyme when it was found to account for a portion (~5%) of estimated 2-AG hydrolase activity in mouse brain (Blankman *et al.*, 2007). ABHD6 is an integral membrane protein with its active site facing the interior of the cell (Blankman *et al.*, 2007). Homology modelling suggests that the first nine residues are extracellular, followed by 30 transmembrane

residues and 290 intracellular residues (Bowman and Makriyannis, 2013). In humans, ABHD6 mRNA is found throughout the body, including the brain, the liver, the kidney and the ovary (Li *et al.*, 2009). Prefrontal cortex has high levels of ABHD6, where it is often expressed post-synaptically on the cell membrane of dendritic spines, apposed to immunoreactive CB₁ receptors (Marrs *et al.*, 2010). ABHD6 was also expressed post-synaptically in cultured hippocampal neurons and glia (Straiker *et al.*, 2009; Marrs *et al.*, 2010). Quantitative immunogold labelling found that more than 90% of ABHD6 immunoreactivity in mouse prefrontal cortex was post-synaptic, often in dendritic spines (Marrs *et al.*, 2010). In mouse retina, ABHD6 immunostaining was present in the inner plexiform layer, the inner nuclear layer and the ganglion cell layer. This staining also appeared to be concentrated in calbindin-positive and GAD67-positive amacrine cells, and also co-localized with a dendritic marker (Hu *et al.*, 2010). Thus, ABHD6 has a relatively widespread distribution, primarily as a post-synaptic protein, contrasting with the pre-synaptic localization of MAGL.

A functional role for ABHD6 in 2-AG hydrolysis is apparent in BV-2 cells (a microglial cell line), which lack MAGL, yet efficiently hydrolyse 2-AG (Muccioli *et al.*, 2007). In these cells, ABHD6 was found to be a significant 2-AG metabolizing enzyme, responsible for about half of 2-AG hydrolysis (Marrs *et al.*, 2010). Additionally, roles for ABHD6 in 2-AG hydrolysis have been reported in lysates of cultured cortical cells and intact cultured cortical neurons (Marrs *et al.*, 2011).

Inhibition of ABHD6 or MAGL in prefrontal cortical slices enabled a subthreshold long-term depression (LTD) stimulus to produce LTD via a CB₁ receptor-dependent mechanism. However, the effects of ABHD6 and MAGL inhibition were not additive – blocking both ABHD6 and MAGL did not further increase LTD. Because its active site is predicted to be intracellular, it has been proposed that ABHD6 limits intracellular 2-AG accumulation (Marrs *et al.*, 2010). Interestingly, even though cultured autaptic hippocampal neurons expressed immunoreactive ABHD6, neither ABHD6 inhibition nor its overexpression affected DSE in these neurons (Straiker *et al.*, 2009). Similarly, ABHD6 inhibition did not alter the time course of depolarization-induced suppression of inhibition (DSI) in cortical slices (Marrs *et al.*, 2010). Its dendritic localization and more limited effects on endocannabinoid-mediated synaptic plasticity may indicate that ABHD6 is most relevant during prolonged 2-AG release (e.g. during an LTD stimulus) or when excessive 2-AG levels are reached.

ABHD12: role in an inherited neurological disorder and a specialized means of 2-AG degradation

ABHD12 accounted for about 9% of estimated 2-AG serine hydrolase activity in the mouse brain (Blankman *et al.*, 2007). ABHD12 is predicted to be an integral membrane protein with its active site facing the lumen/extracellular space (Blankman *et al.*, 2007). In cultured hippocampal neurons, ABHD12 immunoreactivity co-localizes with the Golgi apparatus as detected by the lectin, GS-II (Straiker *et al.*,

2013). Moreover, in contrast with other 2-AG hydrolysing enzymes, ABHD12 has been linked to a neurodegenerative disease in humans characterized by polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataracts (PHARC; Fiskerstrand *et al.*, 2010). This disorder is due to loss-of-function mutations of the ABHD12 gene. ABHD12 KO mice have recently been generated (Blankman *et al.*, 2013) and these mice appear normal at a young age, but go on to develop a number of pathologies later in life that resemble PHARC. However, the available evidence suggests that 2-AG hydrolysis by ABHD12 is unrelated to the deficits noted in ABHD12 KO mice. The evidence for this is that 2-AG levels were not significantly altered in these KO mice and 2-AG hydrolysis activity in brain protein homogenates of ABHD12 KO and wild-type mice were comparable. However, pretreatment of the brain protein homogenates with the selective MAGL inhibitor, JZL184 (1 μ M), reduced 2-AG hydrolase activity in ABHD12 KO animal homogenates significantly more than in wild-type brain homogenates (Blankman *et al.*, 2013). One interpretation of these data is that ABHD12 is an accessory enzyme that is recruited only when particularly high amounts of 2-AG are present or MAGL is unavailable. In young ABHD12 KO mice, very long chain lysophosphatidylserine (lysoPS) lipids were significantly elevated, prior to the onset of neuroinflammatory and behavioural defects. This correlated with an increase in activated microglia in cerebellar sections of asymptomatic ABHD12 KO mice (Blankman *et al.*, 2013). These data suggest that ABHD12 metabolizes very long chain lysoPS lipids, but has little effect on basal 2-AG levels, at least at the global level. Consistent with these observations, overexpression of ABHD12 in autaptic hippocampal neurons did not shorten the duration of DSE, suggesting that in this system, ABHD12 does not contribute to degrading 2-AG in its role as a retrograde messenger (Straiker *et al.*, 2011). However, knockout of ABHD12 did slightly attenuate EPSC inhibition after the longest depolarization, which corresponded to the largest 2-AG release, suggesting that in the case of 2-AG overproduction, ABHD12 might be involved in its breakdown. Moreover, with increasing time in culture, desensitization of CB₁ receptors in ABHD12 KO neurons occurred, supporting a role of ABHD12 in 2-AG clearance under certain conditions (Straiker *et al.*, 2013).

COX-2 oxygenates 2-AG to produce pro-inflammatory prostaglandin glycerol esters

COX-2 is a prostaglandin-endoperoxide synthase that is essential in the synthesis of prostaglandins from free AA (Xie *et al.*, 1991) but it also metabolizes 2-AG (Kozak *et al.*, 2000) to prostaglandin E₂-glycerol ester (PGE₂-G). COX-2 expression is induced by various inflammatory and other injurious stimuli and is a major producer of prostaglandins during an inflammatory response (Masferrer *et al.*, 1994). PGE₂-G is a multifunctional signalling molecule whose effects include immune system modulation, hyperalgesia and enhanced neuronal activity (Sang and Chen, 2006; Sang *et al.*, 2006; Hu *et al.*, 2008). COX-2 inhibition was also shown to prolong DSI in hippocampal slices (Kim and Alger, 2004), suggesting that

it is involved in limiting the retrograde signalling actions of 2-AG. A subsequent study in cultured hippocampal neurons identified a subpopulation of inhibitory interneurons in which the duration of DSI was determined by both MAGL and COX-2 (Straiker and Mackie, 2009). These results suggest that in some inhibitory neurons, COX-2 and MAGL cooperatively determine the duration of DSI, whereas in other inhibitory neurons, MAGL may be the dominant 2-AG degrading enzyme.

CNS insults such as ischaemia, trauma and seizures all lead to COX-2 induction (Lapchak *et al.*, 2001; Takemiya *et al.*, 2003). Interestingly, in cultured autaptic hippocampal neurons, overexpression of COX-2 with endogenous MAGL shortened the duration of DSE by almost a half (Straiker *et al.*, 2011). Additionally, because 2-AG production during CNS insults can be neuroprotective (Sinor *et al.*, 2000; Panikashvili *et al.*, 2001), induction of COX-2 may enhance neurotoxicity, both by decreasing 2-AG levels and by transforming 2-AG into the excitatory neuromodulator PGE₂-G. Taken together, these data demonstrate that COX-2 can profoundly influence 2-AG signalling.

Interestingly, the products of 2-AG metabolism by COX-2 generally oppose CB₁ receptor-mediated 2-AG functions. COX-2 oxygenation of 2-AG has been implicated in glutamate-induced excitotoxicity (Sang *et al.*, 2006), through PGE₂-G activation of caspase 3, ERK, p38 mitogen-activated protein kinase, IP₃ and NF- κ B signalling (Sang *et al.*, 2007). Taken together, the data suggest that antagonism of the PGE₂-G receptor or novel inhibitors of COX-2-mediated PGE₂-G formation could be used to treat neurodegenerative and inflammatory diseases. Recent studies demonstrate that it is possible to develop COX inhibitors that preferentially inhibit oxygenation of 2-AG (Duggan *et al.*, 2011). For example, lumiracoxib inhibited COX-2 oxygenation of 2-AG, without affecting oxygenation of AA whereas celecoxib inhibited AA oxygenation more effectively than that of 2-AG (Duggan *et al.*, 2011). This selective inhibition of 2-AG oxygenation appears to be therapeutically beneficial, as it was efficacious in a mouse model of anxiety (Hermanson *et al.*, 2013) and would avoid the effects of impaired prostaglandin formation.

While less well studied, a number of lipoxygenases can metabolize 2-AG, producing hydroperoxy derivatives of 2-AG (Kozak and Marnett, 2002). In COS-7 cells, arachidonate 12-lipoxygenase was shown to convert 2-AG into the 2-glycerol ester of 12(S)-hydroperoxyeicosa-5,8,10,14-tetraenoic acid (Moody *et al.*, 2001). However, these mechanisms remain to be studied in detail or *in vivo*, especially with regard to their significance in the CNS.

FAAH – another enzyme that can break down 2-AG?

FAAH is a dimeric integral membrane protein. Although it is found throughout the body, it is most active in the brain and liver. In brain homogenates, hippocampus and cortex appear to have the highest FAAH activity (Thomas *et al.*, 1997). The enzyme degrades a variety of fatty acid amides, including AEA (Cravatt *et al.*, 1996). This broad substrate specificity must be

considered when interpreting the results of experiments using FAAH inhibition. In the brain, FAAH immunoreactivity is primarily neuronal and is enriched in somata and dendrites (Egertova *et al.*, 2003), where it is primarily found to be associated with the cytoplasmic face of smooth ER, mitochondria and, less frequently, the cell membrane (Gulyas *et al.*, 2004). Similarly, in cultured hippocampal neurons, FAAH staining was exclusive to neurons and was primarily present in somata and proximal dendrites (Straiker *et al.*, 2011). This staining pattern was in concordance with FAAH lacking rapid effects on synaptic transmission, as the FAAH blocker URB597 did not affect the time course of DSE (Straiker *et al.*, 2011). FAAH can hydrolyse 2-AG *in vitro*, although the consequences of this *in vivo* appear limited (Goparaju *et al.*, 1998). For example, FAAH knockout and FAAH inhibitors generally do not alter 2-AG levels (Lichtman *et al.*, 2002; Kathuria *et al.*, 2003; Schlosburg *et al.*, 2010). Moreover, FAAH knockout did not desensitize CB₁ receptors (Straiker and Mackie, 2005), in contrast to MAGL knockout, which caused profound CB₁ receptor desensitization (Marrs *et al.*, 2010; Schlosburg *et al.*, 2010). However, in autaptic hippocampal cultures, overexpression of FAAH with endogenous MAGL did shorten the duration of DSE (Straiker *et al.*, 2011). In summary, FAAH does not appear to play a role in degrading synaptically released 2-AG in the systems (short-term synaptic plasticity) discussed above; however, if FAAH expression is strongly up-regulated, it may participate.

2-AG phosphorylation and acylation as clearance mechanisms

Lipid kinases with activity against MAG can phosphorylate 2-AG to generate 2-arachidonoyl-LPA (2A-LPA) (Nakane *et al.*, 2002), which is an agonist for LPA receptors (LPA₁-LPA₆) (Choi *et al.*, 2010), and an important signalling molecule in its own right. This modification will decrease 2-AG, attenuating CB₁-receptor-mediated effects, but it will also have the consequence of increasing LPA-mediated signalling. 2A-LPA can also be converted back to 2-AG by lipid phosphatase(s) (Nakane *et al.*, 2002), which provides an alternative route for 2-AG synthesis. One LPA kinase is the multi-substrate lipid kinase (Waggoner *et al.*, 2004), also called acylglycerol kinase (Bektas *et al.*, 2005). Whereas acylation of MAG to a DAG is a theoretical pathway for decreasing 2-AG bioavailability, neither of the two cloned monoacylglycerol acyltransferases, MGAT1 (Yen *et al.*, 2002) or MGAT2 (Cao *et al.*, 2003), are expressed at detectable levels in the CNS. The 2-AG/2A-LPA/LPA cycle demonstrates that inter-conversion of neuromodulators may be an economical means for a cell to simultaneously regulate two signalling systems – by removing an effector from one signalling system and in the process converting it into an effector for another signalling system.

Why do neurons have so many 'options' for degrading 2-AG?

The diversity of enzymes involved in terminating 2-AG signalling allows fine-tuning of this pathway, both spatially and

state-dependently (e.g. following ischemia). In the simplest view, 2-AG is synthesized in the post-synaptic cell. If large amounts of 2-AG are produced, it may be post-synaptically degraded by ABHD6 into AA and glycerol. The remaining 2-AG diffuses across the synapse, interacting with CB₁ receptors on the pre-synaptic terminal. Pre-synaptically, 2-AG can be degraded by MAGL, COX-2 or ABHD12. A summary of this arrangement is depicted schematically in Figure 1. Depending on the amount of 2-AG produced, and the enzymes involved, the duration and spatial spread of 2-AG can be controlled and additional modulators (e.g. PGE₂-G and 2A-LPA) produced.

The last decade has seen many exciting advances in the cannabinoid field. One of them is that 2-AG has emerged as the chief endocannabinoid neuromodulator. Moreover, the field as a whole has moved from brute force manoeuvres to either activate or suppress cannabinoid receptors to more subtle ways of fine-tuning their signalling. One way to achieve this goal is by manipulating 2-AG production or degradation. The various enzymes synthesizing or degrading 2-AG appear to be rich targets for pharmacological manipulation in a variety of disease states. This is not only due to their manipulation affecting 2-AG levels but also because the metabolic products of 2-AG can themselves have significant biological activity.

Acknowledgements

This work was supported by National Institutes of Health grants: DA024628 (N. M.), EY021832 (A. S.), and DA021696 (K. M.).

Conflict of interest

None.

References

- Ahn K, McKinney MK, Cravatt BF (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. *Chem Rev* 108: 1687–1707.
- Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. *Br J Pharmacol* 170: 1449–1867.
- Alger BE, Kim J (2011). Supply and demand for endocannabinoids. *Trends Neurosci* 34: 304–315.
- Atwood BK, Straiker A, Mackie K (2012). CB₂ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. *Neuropharmacology* 63: 514–523.
- Bauer M, Chicca A, Tamborini M, Eisen D, Lerner R, Lutz B *et al.* (2012). Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB₁ receptors. *J Biol Chem* 287: 36944–36967.

- Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S (2005). A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. *J Cell Biol* 169: 801–811.
- Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A *et al.* (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* 163: 463–468.
- Blankman JL, Simon GM, Cravatt BF (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol* 14: 1347–1356.
- Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013). ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. *Proc Natl Acad Sci U S A* 110: 1500–1505.
- Bowman AL, Makriyannis A (2013). Highly predictive ligand-based pharmacophore and homology models of ABHD6. *Chem Biol Drug Des* 81: 382–388.
- Brenowitz SD, Regehr WG (2005). Associative short-term synaptic plasticity mediated by endocannabinoids. *Neuron* 45: 419–431.
- Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. *Biol Psychiatry* 70: 479–486.
- Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007). Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. *J Neurosci* 27: 3695–3702.
- Cao J, Lockwood J, Burn P, Shi Y (2003). Cloning and functional characterization of a mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2. *J Biol Chem* 278: 13860–13866.
- Chanda PK, Gao Y, Mark L, Btsh J, Strassle BW, Lu P *et al.* (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. *Mol Pharmacol* 78: 996–1003.
- Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS *et al.* (2008). Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. *J Biol Chem* 283: 24514–24524.
- Chevalere V, Castillo PE (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. *Neuron* 38: 461–472.
- Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T *et al.* (2010). LPA receptors: subtypes and biological actions. *Annu Rev Pharmacol Toxicol* 50: 157–186.
- Coleman RA, Haynes EB (1986). Monoacylglycerol acyltransferase. Evidence that the activities from rat intestine and suckling liver are tissue-specific isoenzymes. *J Biol Chem* 261: 224–228.
- Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* 384: 83–87.
- Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR *et al.* (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci U S A* 98: 9371–9376.
- Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 34: 605–613.
- Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. *Trends Neurosci* 21: 521–528.
- Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD *et al.* (2011) (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. *Nat Chem Biol* 7: 803–809.
- Egertova M, Cravatt BF, Elphick MR (2003). Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. *Neuroscience* 119: 481–496.
- Farooqui AA, Rammohan KW, Horrocks LA (1989). Isolation, characterization, and regulation of diacylglycerol lipases from the bovine brain. *Ann N Y Acad Sci* 559: 25–36.
- Fiskerstrand T, H'Mida-Ben Brahim D, Johansson S, M'Zahem A, Haukanes BI, Drouot N *et al.* (2010). Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism. *Am J Hum Genet* 87: 410–417.
- Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev* 83: 1017–1066.
- Galiegue S, Mary S, Marchand J, Dussosoy D, Carriere D, Carayon P *et al.* (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 232: 54–61.
- Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M *et al.* (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. *J Neurosci* 30: 2017–2024.
- Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF *et al.* (2013). The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. *Life Sci* 92: 498–505.
- Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. *FEBS Lett* 422: 69–73.
- Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F *et al.* (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur J Neurosci* 20: 441–458.
- Hashimoto Y, Ohno-Shosaku T, Tanimura A, Kita Y, Sano Y, Shimizu T *et al.* (2013). Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde synaptic suppression: evidence for on-demand biosynthesis of 2-arachidonoylglycerol. *J Physiol* 591: 4765–4776.
- Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL *et al.* (2007). Hemopressin is an inverse agonist of CB1 cannabinoid receptors. *Proc Natl Acad Sci U S A* 104: 20588–20593.
- Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR *et al.* (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A* 87: 1932–1936.
- Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ *et al.* (2013). Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. *Nat Neurosci* 16: 1291–1298.
- Higgs HN, Glomset JA (1994). Identification of a phosphatidic acid-preferring phospholipase A1 from bovine brain and testis. *Proc Natl Acad Sci U S A* 91: 9574–9578.

- Ho WS, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. *Br J Pharmacol* 150: 641–651.
- Hohmann AG, Martin WJ, Tsou K, Walker JM (1995). Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. *Life Sci* 56: 2111–2118.
- Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF (2012). DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nat Chem Biol* 8: 999–1007.
- Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM (2008). Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFκappaB activity. *Br J Pharmacol* 153: 1538–1549.
- Hu SS, Arnold A, Hutchens JM, Radicke J, Cravatt BF, Wager-Miller J *et al.* (2010). Architecture of cannabinoid signaling in mouse retina. *J Comp Neurol* 518: 3848–3866.
- Jaeger KE, Dijkstra BW, Reetz MT (1999). Bacterial biocatalysts: molecular biology, three-dimensional structures, and biotechnological applications of lipases. *Annu Rev Microbiol* 53: 315–351.
- Jain T, Wager-Miller J, Mackie K, Straiker A (2013). DAGLα and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons. *Mol Pharmacol* 84: 296–302.
- Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P *et al.* (2008). Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. *Cell Metab* 7: 227–235.
- Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D (2007). A key role for diacylglycerol lipase-α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. *Mol Pharmacol* 72: 612–621.
- Kano M, Ohno-Shosaku T, Maejima T (2002). Retrograde signaling at central synapses via endogenous cannabinoids. *Mol Psychiatry* 7: 234–235.
- Kano M, Ohno-Shosaku T, Hashimoto-dani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. *Physiol Rev* 89: 309–380.
- Kanoh H, Iwata T, Ono T, Suzuki T (1986). Immunological characterization of sn-1,2-diacylglycerol and sn-2-monoacylglycerol kinase from pig brain. *J Biol Chem* 261: 5597–5602.
- Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997). cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. *J Biol Chem* 272: 27218–27223.
- Karlsson M, Reue K, Xia YR, Lusis AJ, Langin D, Tornqvist H *et al.* (2001). Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. *Gene* 272: 11–18.
- Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A *et al.* (2003). Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med* 9: 76–81.
- Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D *et al.* (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. *J Neurosci* 26: 5628–5637.
- Keimpema E, Barabas K, Morozov YM, Tortoriello G, Torii M, Cameron G *et al.* (2010). Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. *J Neurosci* 30: 13992–14007.
- Keimpema E, Mackie K, Harkany T (2011). Molecular model of cannabis sensitivity in developing neuronal circuits. *Trends Pharmacol Sci* 32: 551–561.
- Kim J, Alger BE (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. *Nat Neurosci* 7: 697–698.
- King AR, Lodola A, Carmi C, Fu J, Mor M, Piomelli D (2009). A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. *Br J Pharmacol* 157: 974–983.
- Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF *et al.* (2011). Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. *J Pharmacol Exp Ther* 338: 795–802.
- Kishimoto Y, Kano M (2006). Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. *J Neurosci* 26: 8829–8837.
- Kozak KR, Marnett LJ (2002). Oxidative metabolism of endocannabinoids. *Prostaglandins Leukot Essent Fatty Acids* 66: 211–220.
- Kozak KR, Rowlinson SW, Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. *J Biol Chem* 275: 33744–33749.
- Lapchak PA, Araujo DM, Song D, Zivin JA (2001). Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. *Stroke* 32: 1220–1225.
- Li F, Fei X, Xu J, Ji C (2009). An unannotated alpha/beta hydrolase superfamily member, ABHD6 differentially expressed among cancer cell lines. *Mol Biol Rep* 36: 691–696.
- Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. *J Pharmacol Exp Ther* 302: 73–79.
- Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE *et al.* (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Bio* 5: 37–44.
- Ludanyi A, Hu SS, Yamazaki M, Tanimura A, Piomelli D, Watanabe M *et al.* (2011). Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. *Neuroscience* 174: 50–63.
- Maccarrone M, Salvati S, Bari M, Finazzi A (2000). Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. *Biochem Biophys Res Commun* 278: 576–583.
- Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J *et al.* (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. *Nat Neurosci* 13: 951–957.
- Marrs WR, Horne EA, Ortega-Gutierrez S, Cisneros JA, Xu C, Lin YH *et al.* (2011). Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. *J Biol Chem* 286: 28723–28728.
- Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG *et al.* (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. *Proc Natl Acad Sci U S A* 91: 3228–3232.

- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 346: 561–564.
- Mechoulam R, Gaoni Y (1965). A total synthesis of Δ^1 - Δ^9 -Tetrahydrocannabinol, the active constituent of hashish. *J Am Chem Soc* 87: 3273–3275.
- Moody JS, Kozak KR, Ji C, Marnett LJ (2001). Selective oxygenation of the endocannabinoid 2-arachidonoylglycerol by leukocyte-type 12-lipoxygenase. *Biochemistry* 40: 861–866.
- Moolenaar WH, Kranenburg O, Postma FR, Zondag GC (1997). Lysophosphatidic acid: G-protein signalling and cellular responses. *Curr Opin Cell Biol* 9: 168–173.
- Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM *et al.* (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. *J Neurosci* 27: 2883–2889.
- Mukhopadhyay S, Howlett AC (2001). CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. *Eur J Biochem* 268: 499–505.
- Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L *et al.* (2008). Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. *Proc Natl Acad Sci U S A* 105: 8760–8765.
- Munro S, Thomas KL, Abushaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 365: 61–65.
- Nakane S, Oka S, Arai S, Waku K, Ishima Y, Tokumura A *et al.* (2002). 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. *Arch Biochem Biophys* 402: 51–58.
- Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC *et al.* (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *Science* 334: 809–813.
- Oudin MJ, Hobbs C, Doherty P (2011). DAGL-dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis. *Eur J Neurosci* 34: 1634–1646.
- Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev* 27: 73–100.
- Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R *et al.* (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. *Nature* 413: 527–531.
- Richie-Jannetta R, Nirodi CS, Crews BC, Woodward DF, Wang JW, Duff PT *et al.* (2010). Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2 α glyceryl esters in RAW 264.7 cells and H1819 cells. *Prostaglandins Other Lipid Mediat* 92: 19–24.
- Roloff AM, Anderson GR, Martemyanov KA, Thayer SA (2010). Homer 1a gates the induction mechanism for endocannabinoid-mediated synaptic plasticity. *J Neurosci* 30: 3072–3081.
- Sang N, Chen C (2006). Lipid signaling and synaptic plasticity. *Neuroscientist* 12: 425–434.
- Sang N, Zhang J, Chen C (2006). PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. *J Physiol* 572 (Pt 3): 735–745.
- Sang N, Zhang J, Chen C (2007). COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. *J Neurochem* 102: 1966–1977.
- Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG *et al.* (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. *Nat Neurosci* 13: 1113–1119.
- Shonesy BC, Wang X, Rose KL, Ramikie TS, Cavener VS, Rentz T *et al.* (2013). CaMKII regulates diacylglycerol lipase- α and striatal endocannabinoid signaling. *Nat Neurosci* 16: 456–463.
- Sinor AD, Irvin SM, Greenberg DA (2000). Endocannabinoids protect cerebral cortical neurons from *in vitro* ischemia in rats. *Neurosci Lett* 278: 157–160.
- Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388: 773–778.
- Straiker A, Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. *J Physiol* 569 (Pt 2): 501–517.
- Straiker A, Mackie K (2009). Cannabinoid signaling in inhibitory autaptic hippocampal neurons. *Neuroscience* 163: 190–201.
- Straiker A, Gibson A, Mitjavila J, Blankman J, Hu S, Cravatt B *et al.* (2013). ABHD12 deletion alters cannabinoid signaling and induces desensitization in autaptic hippocampal neurons. 23rd Annual Symposium on The Cannabinoids. International Cannabinoid Research Society: Research Triangle Park, NC, p. 46.
- Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, Cravatt BF *et al.* (2009). Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. *Mol Pharmacol* 76: 1220–1227.
- Straiker A, Wager-Miller J, Hu SS, Blankman JL, Cravatt BF, Mackie K (2011). COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation. *Br J Pharmacol* 164: 1672–1683.
- Sumislawski JJ, Ramikie TS, Patel S (2011). Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. *Neuropsychopharmacology* 36: 2750–2761.
- Szumliński KK, Kalivas PW, Worley PF (2006). Homer proteins: implications for neuropsychiatric disorders. *Curr Opin Neurobiol* 16: 251–257.
- Takemiya T, Suzuki K, Sugiura H, Yasuda S, Yamagata K, Kawakami Y *et al.* (2003). Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling. *Prostaglandins Other Lipid Mediat* 71: 205–216.
- Tanimura A, Yamazaki M, Hashimoto-dani Y, Uchigashima M, Kawata S, Abe M *et al.* (2010). The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase α mediates retrograde suppression of synaptic transmission. *Neuron* 65: 320–327.
- Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, Schoiswohl G *et al.* (2011). Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. *J Biol Chem* 286: 17467–17477.
- Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997). Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. *J Neurosci Res* 50: 1047–1052.
- Waggoner DW, Johnson LB, Mann PC, Morris V, Guastella J, Bajjalieh SM (2004). MuLK, a eukaryotic multi-substrate lipid kinase. *J Biol Chem* 279: 38228–38235.

Won YJ, Puhl HL, 3rd, Ikeda SR (2009). Molecular reconstruction of mGluR5a-mediated endocannabinoid signaling cascade in single rat sympathetic neurons. *J Neurosci* 29: 13603–13612.

Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, Monory K *et al.* (2010). Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. *Eur J Neurosci* 32: 693–706.

Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc Natl Acad Sci U S A* 88: 2692–2696.

Yen CL, Stone SJ, Cases S, Zhou P, Farese RV, Jr (2002). Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase. *Proc Natl Acad Sci U S A* 99: 8512–8517.

Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M *et al.* (2006). Localization of diacylglycerol lipase- α around

postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. *J Neurosci* 26: 4740–4751.

Yoshida T, Uchigashima M, Yamasaki M, Katona I, Yamazaki M, Sakimura K *et al.* (2011). Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. *Proc Natl Acad Sci U S A* 108: 3059–3064.

Zhang L, Wang M, Bisogno T, Di Marzo V, Alger BE (2011). Endocannabinoids generated by Ca^{2+} or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase. *PLoS ONE* 6: e16305.

Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE *et al.* (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. *J Psychopharmacol* 20: 683–686.